Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program

Abstract Introduction Ixekizumab, a highly selective interleukin-17A monoclonal antibody, was approved for the treatment of moderate-to-severe psoriasis (PsO) in 2016. Limited real-world data are available on its effectiveness from a patient’s perspective shortly (2 to 4 weeks) after initiation and...

Full description

Bibliographic Details
Published in:	Dermatology and Therapy
Main Authors:	Alice B. Gottlieb, Russel Burge, William N. Malatestinic, Baojin Zhu, Yunyang Zhao, Julie McCormack, Miriam Kimel, Joseph F. Merola
Format:	Article
Language:	English
Published:	Adis, Springer Healthcare 2023-07-01
Subjects:	Customer support program Ixekizumab Patient-reported outcomes Psoriasis
Online Access:	https://doi.org/10.1007/s13555-023-00969-1

Similar Items

Ixekizumab: an alternative for HIV-positive psoriasis patients
by: Fanghua Liu, et al.
Published: (2024-11-01)

Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab
by: Blauvelt A, et al.
Published: (2020-03-01)

Relationship Between Rapid Skin Clearance and Quality of Life Benefit: Post Hoc Analysis of Japanese Patients with Moderate-to-Severe Psoriasis Treated with Ixekizumab (UNCOVER-J)
by: Masaru Honma, et al.
Published: (2020-09-01)

Ixekizumab Improved Refractory Erythrodermic Psoriasis with Comorbid Diffuse Alopecia: A Case Report with 52-Week Follow-Up
by: Song B, et al.
Published: (2024-08-01)

A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
by: Bruce W. Kirkham, et al.
Published: (2023-07-01)

Long-term management of pediatric psoriasis with ixekizumab: a case report
by: Diego Orsini, et al.
Published: (2023-12-01)

Improvement in general touch avoidance in patients with moderate‐to‐severe genital psoriasis treated with ixekizumab during a 52‐week, randomized, phase 3 clinical trial (IXORA‐Q)
by: Jennifer Soung, et al.
Published: (2023-06-01)

Ixekizumab
by: İlgen Ertam Sağduyu
Published: (2022-04-01)

Severe Generalized Pustular Psoriasis Successfully Treated with Ixekizumab: A Case Report
by: Martina Burlando, et al.
Published: (2022-11-01)

Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes
by: Luís Puig, et al.
Published: (2019-08-01)

Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies
by: April Armstrong, et al.
Published: (2024-03-01)

Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60
by: Alexander Egeberg, et al.
Published: (2024-04-01)

Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes
by: Alexander Egeberg, et al.
Published: (2023-01-01)

Ixekizumab trough concentrations in psoriasis: Paving the way towards personalised therapy: A cohort study
by: Lisa Schots, et al.
Published: (2024-12-01)

Sustained Resolution of Nail Psoriasis Through 5 Years with Ixekizumab: A Post-Hoc analysis from UNCOVER-3
by: Alexander Egeberg, et al.
Published: (2022-10-01)

Efficacy and safety of ixekizumab versus adalimumab in patients with active psoriatic arthritis and moderate-to-severe psoriasis: 52-week results from the randomised SPIRIT-H2H trial
by: Kristian Reich, et al.
Published: (2022-05-01)

The Age Factor in Ixekizumab Survival: Older Patients Show Higher Long-Term Treatment Survival
by: Inés Noval-Martín, et al.
Published: (2025-10-01)

Corrigendum: Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes
by: Alexander Egeberg, et al.
Published: (2023-03-01)

Ixekizumab as a successful treatment in pediatric generalized pustular psoriasis
by: Maria Esposito, et al.
Published: (2025-02-01)

Clinical experience of using Ixekizumab in treatment of a female patient with severe psoriasis and psoriatic arthritis, resistant to the therapy
by: N. V. Kungurov, et al.
Published: (2021-06-01)

Ixekizumab in the treatment of psoriatic arthritis
by: Yu. L. Korsakova, et al.
Published: (2024-12-01)

Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study—IL PSO (Italian Landscape Psoriasis)
by: Mario Valenti, et al.
Published: (2024-05-01)

Assessing the Impact of Improvements in PASI and Itch Scores on Patients’ Quality of Life in the Treatment of Psoriasis
by: Gil Yosipovitch, et al.
Published: (2019-07-01)

Successful Treatment of Linear Psoriasis With the IL-17a-Antagonist Ixekizumab: A Case Report
by: Christov S, et al.
Published: (2025-01-01)

Real-world evidence for ixekizumab in the treatment of psoriasis and psoriatic arthritis: literature review 2016–2021
by: Adam Reich, et al.
Published: (2023-12-01)

Long-Term Safety of Ixekizumab Treatment in Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: a Post Hoc Analysis of Cerebro-Cardiovascular Events
by: Mark Lebwohl, et al.
Published: (2025-01-01)

The efficacy of the interleukin 17 inhibitor ixekizumab in psoriatic arthritis: data from real clinical practice
by: I. M. Marusenko, et al.
Published: (2021-06-01)

Rare Case Report of Primary Active Pulmonary Tuberculosis During Ixekizumab Treatment for Plaque Psoriasis
by: Li Y, et al.
Published: (2024-07-01)

Integrated Safety Analysis on Skin Cancers among Patients with Psoriasis Receiving Ixekizumab in Clinical Trials
by: Saxon D. Smith, et al.
Published: (2023-06-01)

Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity
by: April W. Armstrong, et al.
Published: (2024-05-01)

Effects of secukinumab and ixekizumab on major adverse cardiovascular events in patients with psoriasis: a meta-analysis of randomized controlled trials
by: Yonghong Zhang, et al.
Published: (2024-03-01)

Effectiveness of Ixekizumab in Elderly Patients for the Treatment of Moderate-to-Severe Psoriasis: Results From a Multicenter, Retrospective Real-Life Study in the Lazio Region
by: Annunziata Dattola, et al.
Published: (2024-07-01)

Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials
by: Craig Leonardi, et al.
Published: (2020-03-01)

Risk Factors of Ixekizumab-Induced Injection Site Reactions in Patients with Psoriatic Diseases: Report from a Single Medical Center
by: I-Heng Chiu, et al.
Published: (2023-06-01)

Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials
by: Atul Deodhar, et al.
Published: (2024-02-01)

Successful Treatment of Ixekizumab-Induced Paradoxical Eczematous Reaction with JAK Inhibitors: A Case Report
by: Fu J, et al.
Published: (2025-09-01)

Generalized hypertrichosis associated with the use of interleukin 17 blockers in 2 patients with psoriasis
by: Luis E. Sánchez-Dueñas, MD, et al.
Published: (2020-07-01)

Biologics for the Treatment of Severe Acrodermatitis Continua of Hallopeau: Report of Two Cases Successfully Treated with Ixekizumab and Ustekinumab
by: Luigi Gargiulo, et al.
Published: (2023-04-01)

Ixekizumab is effective in the long-term management in moderate-to-severe plaque psoriasis: results from an Italian retrospective cohort study (the LOTIXE study)
by: Andrea Chiricozzi, et al.
Published: (2023-12-01)

Clinical efficacy, drug retention and recurrence of ixekizumab across psoriasis severities: a multicenter retrospective analysis of 354 patients
by: Zhuhui Qiao, et al.
Published: (2025-12-01)